Therefore, Aur-A deregulation and subsequent activation of the SKP2 pathway plays an important role in ccRCC tumorigenesis and provide a supporting justification for clinical trials to evaluate combined Aur-A and SKP2 inhibitors to enhance the anti-ccRCC effects observed with single-agent inhibitor alone. Here, SKP2 is linked to nonpapillary renal cell carcinoma.